Clinical trial · Interventional
Autotaxin (ATX) as a Marker for Breast Cancer
NCT04328194CI-TRIAL-00044353unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is the leading cause of cancer death in women worldwide. According to the GLOBOCAN 2018 worldwide estimates of cancer incidence and mortality, in 2018, about 2,088,849 new cases were diagnosed and approximately 626,679 women were predicted to die from the disease . It is the leading cause of cancer related mortality, representing15% of deaths per year worldwide .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breast ultrasound or mammography | Diagnostic Test | — | UNRESOLVED |
| Cancer Antigen 15-3 (CA15-3). | Diagnostic Test | — | UNRESOLVED |
| chest x-ray | Radiation | — | UNRESOLVED |
| Full clinical examination | Other | — | UNRESOLVED |
| Full medical history | Other | — | UNRESOLVED |
| Histopathological examination of breast mass specimens | Diagnostic Test | — | UNRESOLVED |
| Magnetic Resonance Imaging ( MRI) and Bone scan | Radiation | — | UNRESOLVED |
| Peripheral haemogram | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Study Group
- description
- 80 patients with breast cancer
- interventionNames
- Diagnostic Test: Serum Autotaxin
- Radiation: chest x-ray
- Diagnostic Test: Breast ultrasound or mammography
- Diagnostic Test: Histopathological examination of breast mass specimens
- Radiation: Magnetic Resonance Imaging ( MRI) and Bone scan
- Diagnostic Test: Peripheral haemogram
- Diagnostic Test: Renal and liver functions
- Diagnostic Test: Prothrombin time and concentration
- Diagnostic Test: Cancer Antigen 15-3 (CA15-3).
- Other: Full medical history
- Other: Full clinical examination
- type
- PLACEBO_COMPARATOR
- label
- Control Group
- description
- 20 healthy controls aged ( 19 to 69 years ) from healthy volunteers after informed consent.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: * The study will be conducted on one hundred female individuals; 80 newly diagnosed breast cancer patients before any treatment or surgical intervention and 20 apparently normal female individuals. Exclusion Criteria: * Patients with any other type of malignant or benign tumors, renal failure, cardiovascular diseases and liver cirrhosis were excluded from our study. * Past history of chemotherapy or surgical treatment of any malignancy. * Inflammatory diseases (e.g.bronchitis) or autoimmune diseases (e.g.rheumatoid arthritis).
References
Publications (24)
- RESULTBoucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004 Dec;114(12):1714-25. doi: 10.1172/JCI22123. PMID 15599396
- RESULTBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. PMID 30207593
- RESULTChoi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157-86. doi: 10.1146/annurev.pharmtox.010909.105753. PMID 20055701
- RESULTDusaulcy R, Rancoule C, Gres S, Wanecq E, Colom A, Guigne C, van Meeteren LA, Moolenaar WH, Valet P, Saulnier-Blache JS. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res. 2011 Jun;52(6):1247-1255. doi: 10.1194/jlr.M014985. Epub 2011 Mar 18. PMID 21421848
- RESULTFerry G, Tellier E, Try A, Gres S, Naime I, Simon MF, Rodriguez M, Boucher J, Tack I, Gesta S, Chomarat P, Dieu M, Raes M, Galizzi JP, Valet P, Boutin JA, Saulnier-Blache JS. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem. 2003 May 16;278(20):18162-9. doi: 10.1074/jbc.M301158200. Epub 2003 Mar 17. PMID 12642576
- RESULTHinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 2007 Apr;7(4):309-15. doi: 10.1038/nrc2113. PMID 17384585